Development of novel therapeutic antibodies via computational design

Antibody discovery

Antibody humanization and optimization

Antibody production and characterization

Bispecific antibody development

Internalization antibody development

Speaker

During her 22-year research and development of antibody drugs, Dr. Liu Yue led and participated in 14 therapeutic antibody studies on various diseases, including the development of anti-thrombotic antibodies for myocardial infarction and venous embolization for guided imaging and guided thrombolysis; Tumor-specific endocytosis antibodies are used for antibody-conjugated drug therapy for tumors, Alzheimer's and Parkinson's syndrome, macular degeneration, and the development of therapeutic antibodies against a variety of rare diseases. Two of these antibodies have entered phase II clinical. Dr. Liu worked for DigitAb Inc. (2007-08), UCSF (2009-11), Elan Pharmaceuticals (2011-12) and Prothena Bioscience (2012-16) and was the head of the innovation club at Prothena. In early 2017, She co-founded Ab Studio Inc. in San Francisco Bay Area.

在22年的抗体药物研发生涯中，刘跃博士领导和参与过多种疾病的14个治疗用抗体研究，包括研发抗血栓抗体对心肌梗塞和静脉栓塞进行导向显像和导向溶栓；能被肿瘤特异性内吞的抗体对肿瘤进行抗体偶联药物治疗；针对阿兹海默症和帕金森氏综合症、视网膜黄斑病变及研发针对多种罕见病的治疗用抗体。其中两个抗体已进入Ⅱ期临床。刘博士曾供职于DigitAb Inc.（2007-08），UCSF （2009-11），Elan Pharmaceuticals （2011-12）和Prothena Bioscience （2012-16）并担任Prothena的创新俱乐部负责人。2017年初作为共同创始人在旧金山湾区创建了Ab Studio Inc.。

When

June 21 (Sat), 2018

6:30 – 7:00 pm Networking

7:00 – 8:30 pm Seminar 

Where

Irvine Ranch Water District, 15500 Sand Canyon Ave., Irvine, CA 92618 

Free Registration

Registration is free but required (max 70 registrants). Parking is free. Light food/snacks are provided. 

Questions

http://www.sabpa-ocla.org

Email:   Sabpa.ocla@gmail.com